PMID- 35846980 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220719 IS - 2666-6065 (Electronic) IS - 2666-6065 (Linking) VI - 27 DP - 2022 Oct TI - Demonstration of a population-based HCV serosurvey in Ho Chi Minh City, Viet Nam: Establishing baseline prevalence of and continuum of care for HCV micro-elimination by 2030. PG - 100524 LID - 10.1016/j.lanwpc.2022.100524 [doi] LID - 100524 AB - BACKGROUND: A baseline of hepatitis C virus (HCV) burden and other HCV epidemiological profiles is necessary for HCV micro-elimination in Ho Chi Minh City (HCMC), Viet Nam. This study aimed to determine HCV exposure and prevalence of HCV viremia as well as the proportion of HCV testing and treatment uptake among participants. METHODS: From 2019 to 2020, the probability proportionate to size sampling method was deployed to representatively invite approximately 20,000 adults (18 or older) throughout HCMC to free screening and linkage to care for HCV. FINDINGS: In HCMC, the weighted prevalence of anti-HCV was 1.3% (95% CI, 1.1%-1.6%). Individuals born from 1945 to 1964 had the anti-HCV prevalence of 3.6% (95% CI, 3.0%-4.2%) and represented 40.4% of all HCV cases. There were wide variations in anti-HCV prevalence in HCMC, including variations between districts, risk factors, and socioeconomic statuses. A baseline HCV continuum of care for the city demonstrated that only 28.5% (85/298, 95%CI 23.4-33.7%) of persons with anti-HCV (+) were aware of their HCV status, with 77.6% (66/85, 95%CI 68.8-86.5%) diagnosing HCV incidentally, 82.7% (62/75, 95%CI 74.1-91.2%) initiating anti-HCV therapy, and 53.6% (30/56, 95%CI 40.5-66.6%) achieving HCV cures. INTERPRETATION: There remains a considerable disease burden of HCV in HCMC of which a significant proportion was in the age group born between 1945 to 1964. Additionally, there were significant gaps in HCV awareness, screening, and access to care in the community in Viet Nam. Thus, future interventions must have pragmatic targets, be tailored to the local needs, and emphasise screening. FUNDING: This work was supported by investigator-sponsored research grants from Gilead Sciences Inc. (Grant No: IN-US-987-5382); Roche Diagnostic International Ltd. (Grant No. SUB-000196); and in-kind donations from Abbott Diagnostic Viet Nam; Hepatitis B Foundation; Medic Medical Center, Viet Nam; Johns Hopkins University School of Medicine's Center of Excellence for Liver Disease in Viet Nam; and the Board of Directors, Viet Nam Viral Hepatitis Alliance (V-VHA). CI - (c) 2022 The Authors. FAU - Kim, Thanh V AU - Kim TV AD - Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. FAU - Le, Duc H AU - Le DH AD - Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. FAU - Dao, Diem V B AU - Dao DVB AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. FAU - Pham, Trang Ngoc Doan AU - Pham TND AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. AD - University of Illinois at Chicago, Chicago, IL, USA. FAU - Mize, Gary W AU - Mize GW AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. FAU - Phan, Loc T B AU - Phan LTB AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. FAU - Nguyen, Dan X AU - Nguyen DX AD - Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. FAU - Ngo, Thi-Thuy-Dung AU - Ngo TT AD - Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. FAU - Gish, Robert G AU - Gish RG AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. FAU - Lee, William M AU - Lee WM AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. AD - UT Southwestern Medical Center, Dallas, TX, USA. FAU - Trang, Amy AU - Trang A AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. FAU - Le, Anh N AU - Le AN AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. FAU - Chen, Moon Jr AU - Chen M Jr AD - University of California at Davis, Davis, CA, USA. FAU - Phan, Hai T AU - Phan HT AD - Medic Medical Center, Ho Chi Minh City, Viet Nam. FAU - Nguyen, Binh T AU - Nguyen BT AD - Ho Chi Minh City Department of Health, Ho Chi Minh City, Viet Nam. FAU - Tang, Hong K AU - Tang HK AD - Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam. FAU - Dao, Doan Y AU - Dao DY AD - Vietnam Viral Hepatitis Alliance, Reston, VA, USA. AD - Center of Excellence for Liver Disease in Viet Nam, Johns Hopkins University School of Medicine, Baltimore, MD, USA. LA - eng PT - Journal Article DEP - 20220709 PL - England TA - Lancet Reg Health West Pac JT - The Lancet regional health. Western Pacific JID - 101774968 PMC - PMC9283666 OTO - NOTNLM OT - 2030 OT - Access to care OT - Framework OT - HCV baseline linkage to care OT - HCV screening OT - Hepatitis C virus OT - Ho Chi Minh City (HCMC) OT - Micro-elimination OT - National elimination OT - Viet Nam COIS- Moon Chen Jr received consulting fees from Vietnam Viral Hepatitis Alliance. RGG has received grants or research support in last 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG is a member of Topography Health clinical trials alliance. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm/Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with Abbvie, Abbott, Access Biologicals, Active Genome Expressed Diagnostics, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals Inc, Ark Biopharmaceutical Co Ltd, Arrowhead, Arterys Inc, Alexion, Altimmune, Antios Therapeutics, AprosTx, Audentes Therapeutics, Bayer, Bausch/Salix, Cirina, Consumer Health Products Assoc, CymaBay Therapeutics Inc, DiaSorin Inc, Dova Pharmaceuticals, DRG Abacus, DURECT Corporation, Dynavax, Echosens, Eiger, Eisai, Enyo, Exelixis, Fibronostics Inc, Forty-Seven Inc, Fujifilm Wako Diagnostics, Gilead, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen/J&J, KannaLife, Kezar Life Sciences Inc, LabCorp, Laboratory for Advanced Medicine, Labyrinth Holdings, Life Line Screening, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Perspectum, Pfizer, Pharmaceutical Research Associates, ProdigY Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Sagimet Inc, Salix, Saol Bermuda Ltd, Shenzhen HEC Industrial Development, Shionogi Inc, Spring Bank, Tonghua Anrate Biopharmaceutical, Topography Health, Trimaran, Venatorx, and Viravaxx AG. RGG reports activities for Speakers Bureau, focusing on HBV, HCV, HDV and liver cancer; specifically, epidemiology, diagnosis, and treatment. In addition, program presentations on vaccination for HBV and management of complications of cirrhosis. RGG has speaker's contracts to do promotional talks for AbbVie, BMS, Eisai, Genentech, Gilead Sciences Inc., and Intercept. RGG is a minor stock shareholder (liver space noted only) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, AngioCrine, and HepaTx, outside the submitted work. The rest of the authors declare no competing interests. EDAT- 2022/07/19 06:00 MHDA- 2022/07/19 06:01 PMCR- 2022/07/09 CRDT- 2022/07/18 04:09 PHST- 2022/07/18 04:09 [entrez] PHST- 2022/07/19 06:00 [pubmed] PHST- 2022/07/19 06:01 [medline] PHST- 2022/07/09 00:00 [pmc-release] AID - S2666-6065(22)00139-0 [pii] AID - 100524 [pii] AID - 10.1016/j.lanwpc.2022.100524 [doi] PST - epublish SO - Lancet Reg Health West Pac. 2022 Jul 9;27:100524. doi: 10.1016/j.lanwpc.2022.100524. eCollection 2022 Oct.